ArticleRespirology case reports2025
Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Diagnostic Dilemma.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Diagnostic Dilemma.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Primary pulmonary lymphoma (PPL) is a rare clonal proliferation of lymphoid tissue confined to the lungs, representing only 0.5%-1% of all lung neoplasms. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is the most common subtype and is often associated with chronic inflammation and autoimmune conditions. Diagnosis is challenging given its indolent course, nonspecific clinical features and variable radiographic presentations. We report a 64-year-old female with systemic lupus erythematosus who was incidentally found to have multiple pulmonary nodules. Serial imaging revealed interval growth and biopsy confirmed pulmonary MALT lymphoma. A watchful waiting strategy was initially employed, but subsequent disease progression prompted rituximab therapy, with only mild radiographic response despite preserved clinical stability. This case highlights the diagnostic challenges of pulmonary MALT lymphoma, the variability in treatment response and the potential interplay with autoimmune disease. Further studies are needed to clarify optimal therapeutic approaches, including the role of macrolides and autoimmune-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.